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1  | INTRODUCTION
Glucocorticoids are vital for normal foetal growth and organ devel-
opment, but foetal overexposure to the major circulating glucocorti-
coid, cortisol, is associated with intrauterine growth restriction1 and an 
increased risk of cardiovascular disease in later life.2 During pregnancy, 
a number of endocrine changes cause the maternal hypothalamic- 
pituitary- adrenal (HPA) axis to undergo dramatic activation resulting 
in cortisol levels that are around threefold higher than in nonpreg-
nancy.3-5 Dysregulation of the maternal HPA axis has been implicated 
 
Received: 8 November 2017  |  Revised: 14 December 2017  |  Accepted: 28 December 2017
DOI: 10.1111/cen.13548
O R I G I N A L  A R T I C L E
Pulsatility of glucocorticoid hormones in pregnancy: Changes 
with gestation and obesity
Laura I. Stirrat1  | Jamie J. Walker2,4,5,6 | Ksenia Stryjakowska1 |  
Natalie Jones3 | Natalie Z. M. Homer7 | Ruth Andrew3 | Jane E. Norman1 |  
Stafford L. Lightman2 | Rebecca M. Reynolds1,3
1Tommy’s Centre for Maternal and Fetal 
Health, Medical Research Council Centre for 
Reproductive Health, University of Edinburgh, 
Edinburgh, UK
2Henry Wellcome Laboratories for Integrative 
Neuroscience and Endocrinology, University 
of Bristol, Bristol, UK
3University/BHF Centre for Cardiovascular 
Science, University of Edinburgh, Edinburgh, 
UK
4Wellcome Trust Centre for Biomedical 
Modelling and Analysis, University of Exeter, 
Exeter, UK
5EPSRC Centre for Predictive Modelling in 
Healthcare, University of Exeter, Exeter, UK
6College of Engineering, Mathematics and 
Physical Sciences, University of Exeter, Exeter, 
UK
7Mass Spectrometry Core, Edinburgh Clinical 
Research Facility, University of Edinburgh, 
Edinburgh, UK
Correspondence
Rebecca M. Reynolds, Tommy’s Centre for 
Maternal and Fetal Health, Medical Research 
Council Centre for Reproductive Health, 
University of Edinburgh, Edinburgh, UK.
Email: r.reynolds@ed.ac.uk
Funding information
Medical Research Council, Grant/Award 
Number: MR/N022556/1; Wellcome Trust, 
Grant/Award Number: WT105618MA; 
EPSRC, Grant/Award Number: EP/
N014391/1
Summary
Objective: Hypothalamic- pituitary- adrenal axis (HPA) activity is decreased in obese 
pregnancy and associates with increased foetal size. Pulsatile release of glucocorticoid 
hormones regulates their action in target tissues. Glucocorticoids are essential for nor-
mal foetal growth, but little is known about glucocorticoid pulsatility in pregnancy. We 
aimed to investigate the ultradian rhythm of glucocorticoid secretion during obese and 
lean pregnancy and nonpregnancy.
Design: Serum cortisol, cortisone, corticosterone and 11- dehydrocorticosterone were 
measured by LC- MS/MS from samples obtained at 10- minute intervals between 
08.00- 11.00 hours and 16.00- 19.00 hours, from 8 lean (BMI <25 kg/m2) and 7 obese 
(BMI > 35 kg/m2) pregnant women between 16- 24 weeks gestation and again at 30- 
36 weeks), and nonpregnant controls (lean n = 3, obese n = 4) during the luteal phase 
of their menstrual cycle. Interstitial fluid cortisol was measured by ELISA, from  samples 
obtained using a portable microdialysis and automated collection device at 20- minute 
intervals over 24 hours.
Results: Serum cortisol AUC, highest peak and lowest trough increased significantly with 
gestation in lean and obese pregnant compared with nonpregnant subjects. Pulsatility of 
cortisol was detected in interstitial fluid. In pregnant subjects, interstitial fluid pulse fre-
quency was significantly lower with advancing gestation in obese, but not in lean.
Conclusions: We demonstrate cortisol pulsatility in interstitial fluid. Pulse frequency is 
altered with increased gestation and BMI. This may be a novel mechanism to explain 
decreased HPA activity in obese pregnancy.
K E Y W O R D S
glucocorticoids, human pregnancy, obesity, pulsatility
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in pregnancy complications including preterm birth6 and preeclamp-
sia.7,8 The glucocorticoid corticosterone, which is known to circulate 
at significantly lower levels than cortisol in nonpregnancy,9 is increas-
ingly being recognized as a key player in HPA axis regulation.10 It has 
been suggested that the foetus preferentially secretes corticosterone 
over cortisol in response to stress, and therefore has been proposed to 
be an important biomarker of foetal stress at the time of delivery,11,12 
but little is known about how it changes during pregnancy.
The circadian rhythm of the HPA axis, which in humans is charac-
terized by peak levels of cortisol early in the morning, is maintained 
in pregnancy.13 More detailed studies of circadian rhythmicity in ani-
mals14 and in nonpregnant humans15 have identified an underlying “ul-
tradian rhythm”16 of cortisol pulses within blood and target tissues,17 
occurring approximately once per hour.16,18,19 Pulse amplitude and 
frequency increase during the circadian peak of secretion when cir-
culating cortisol levels are at their highest16 and in response to food.20 
These pulses are important for optimal gene transcription and meta-
bolic functions.21 Altered ultradian rhythm patterns have been linked 
to pathological consequences and manifestations of disease21 such as 
psychotic and depressive states,22,23 where elevated troughs at the 
nadir result in a flattened circadian rhythmicity. In pregnancy, excess 
glucocorticoid exposure is thought to induce a long- lasting effect 
on peripheral tissue expression of glucocorticoid- sensitive genes.24 
However, the underlying mechanisms for such changes are unknown. 
One study of cortisol pulsatility in pregnancy used 30- minute serum 
sampling and detected 2- 3 pulses of cortisol in 12 hours in the third 
trimester of human pregnancy,25 but the authors acknowledged that 
30- minute sampling was suboptimal for accurate detection of pulse 
rates of hormones with rapid clearance rates. Whether or not and how 
the ultradian rhythm of cortisol secretion changes across gestation is 
unknown. This information will improve understanding of pathways to 
foetal growth as well as the aetiology of pregnancy complications.
We aimed to determine whether there are changes in cortisol pulsa-
tility in 2 physiological contexts of altered HPA axis activity; firstly, the 
increase in circulating cortisol levels that occur with advancing gestation, 
and secondly, in maternal obesity, where we and others have reported 
lower maternal circulating cortisol levels in obese than in lean pregnant 
women.26,27 We hypothesized that pulse amplitude and frequency 
would increase with advancing gestation and that these characteris-
tics would be lower in obese compared with lean pregnant women. To 
test this hypothesis, we studied daytime serum profiles of both cortisol 
and corticosterone as well as their inactive metabolites (cortisone and 
11- dehydrocorticosterone, respectively), and 24- hour interstitial fluid 
cortisol levels in obese and lean pregnant, and nonpregnant women. 
We conducted more frequent sampling than has previously been per-
formed25 to maximize the likelihood of detecting cortisol pulses.
2  | SUBJECTS AND METHODS
2.1 | Subjects and clinical protocol
We recruited lean (BMI 18.5- 24.9 kg/m2) pregnant (LP; n = 8), obese 
(BMI ≥ 30 kg/m2) pregnant (OP; n = 7), lean nonpregnant (LNP; 
n = 3) and obese nonpregnant (ONP; n = 4) women. One obese par-
ticipant was studied in nonpregnancy and again during pregnancy. 
Pregnant women were recruited from antenatal clinics in NHS 
Lothian. Nonpregnant volunteers were recruited from the University 
of Edinburgh, and community weight loss clinics in NHS Lothian. 
Eligible pregnant women were Caucasian and had a normal booking 
ultrasound scan and a singleton pregnancy. Nonpregnant women had 
a regular menstrual cycle and did not use hormonal contraception. 
Exclusion criteria were smoking, pre- existing diabetes, regular glu-
cocorticoid medication, severe mental health disorder and anaemia. 
Ethical approval and written informed consent were obtained.
Participants attended study visits at the Edinburgh Clinical 
Research Facility, Royal Infirmary of Edinburgh. Pregnant women at-
tended for study visits at 16- 24 weeks’ gestation and between 30- 
36 weeks’ gestation, and nonpregnant volunteers attended for one 
study visit in the luteal phase of the menstrual cycle.
At each study visit, fasting blood samples were obtained at 10- minute 
intervals between 08.00- 11.00 hours and between 16.00- 19.00 hours 
via a peripheral venous cannula. Subcutaneous interstitial fluid samples 
for measurement of free cortisol28 were obtained at 20- minute intervals 
over 24 hours by microdialysis. A linear microdialysis catheter (Linton, 
Norfolk, UK) was inserted subcutaneously into the interstitial compart-
ment of the anterior abdominal wall and collected via a novel, miniatur-
ized, portable collection device as described by Bhake et al15
Serum was separated immediately and stored at −80°C for later 
laboratory analysis. Clinical outcomes including maternal booking 
BMI, gestation at delivery, birthweight and offspring gender were ex-
tracted from medical records.
2.2 | Laboratory methods
2.2.1 | Liquid chromatography- tandem mass 
spectrometry (LC- MS/MS)
We measured cortisol, cortisone, corticosterone and 
11- dehydrocorticosterone simultaneously by liquid chromatography- 
tandem mass spectrometry, using a Waters Acquity™ UPLC (Manchester, 
UK), liquid chromatography system followed by mass spectral analysis on 
an ABSciex QTRAP® 5500 (Warrington, UK) mass spectrometer. Mass 
spectral conditions are described in Table S1 in conjunction with ion spray 
voltage (5500 V) and source temperature (700°C). Following enrichment 
of serum (200 μl) with internal standards, epi- cortisol (25 ng; Steraloids, 
USA), epi- corticosterone (25 ng; Steraloids, USA) and 9,12,12,12 [2H4]- 
cortisol (D4- cortisol 25 ng; QMX Laboratories, England, UK), and dilution 
with water (200 μl) analytes were extracted via supported liquid extraction 
(ISOLUTE® SLE+ 400 μl 96- well plate, Biotage, Sweden) and eluted with 
98:2 dichloromethane:2- propanol. Analytes were separated on an ACE 
Excel 2 C18- AR (150 × 2.1 mm, 2 μm) column (Advanced Chromatography 
Technologies Ltd, UK) at 40 °C. The elution process started with 70:30 
water with 0.1% formic acid (FA) (solution A) and acetonitrile with 0.1% 
FA (solution B) was maintained for 4 minutes followed by a 1- minute linear 
rise to 60% solution B, a subsequent rise to 90% solution B, before return-
ing to 30% solution B by 6.1 minutes at a constant flow rate of 0.5 mL/min.
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Validation parameters (intra- and interassay precision, accu-
racy; Table S2) were within acceptable limits (the lowest levels 
being acceptable <20% RSD with all following <15%). Levels of cor-
ticosterone and 11- dehydrocorticosterone in some samples were 
close to or below the limit of quantification in all subjects and at all 
gestations of pregnancy. The ratios of cortisol: cortisone and corti-
costerone: 11- dehydrocorticosterone were used as a marker of 11beta- 
hydroxysteroid dehydrogenase type 2 (11β- HSD2) enzyme activity.
Commercially available ELISA kits were used for the analysis of 
plasma ACTH (Demeditec DE3467; interassay CV 6.9- 7.1%) and in-
terstitial fluid cortisol (IBL International RE52611; interassay CV 4.2- 
17.0%), as previously used by Bhake et al15 Free cortisol values were 
expected to be above the top standard, therefore were diluted to 1:10 
in the assay zero standard and results were corrected for dilution.
2.3 | Statistical analysis
Data distribution was assessed for normality by visually assessing histo-
grams. Data that were not normally distributed were normalized using 
the natural- log transformation. The independent t test was used to test 
for differences in subject characteristics between continuous variables 
and chi- squared test for categorical variables. For cortisol measure-
ments, the “highest peak” was the highest value in any given profile, 
and the “lowest trough” was the lowest value. The area under the curve 
(AUC) for hormone profiles was used as a marker for total glucocorticoid 
levels over the study period. Pulse analysis was performed using Cluster 
analysis,29 a statistically rigorous peak detection algorithm that has been 
widely used to quantify the pulsatile dynamics of various hormones, in-
cluding cortisol.30 The algorithm detected statistically significant intersti-
tial fluid cortisol pulses, pulse frequency (pulses/hours), pulse height (μg/
dl) and mean concentration (μg/dl) in a given cortisol time series. Cluster 
parameters used in the analysis were as follows: minimum detectable 
concentration of the assay (MDC, 0.015 μg/dl); intra- assay coefficient of 
variation (CV, 12.08%); test cluster size for sliding nadir (2.0); test cluster 
size for sliding peak (1); t- statistic for significant increase in the data (2.0); 
t- statistic for significant decrease in the data (2.0); and minimum peak 
size (0.0 μg/dl). One- way ANOVA was used to compare changes in pulse 
characteristics between different groups. The paired t test was used to 
assess differences in pulse characteristics between pregnant women 
who attended for 2 study visits. Analysis was performed using SPSS v21 
(IBM). Data in text are mean ± (SD), and data in figures are mean ± SEM. 
Statistical significance was considered at P < .05.
3 | RESULTS
3.1 | Demographics
Maternal and neonatal characteristics are demonstrated in Table 1. In 
pregnant participants, OP were younger and had higher systolic and 
diastolic blood pressure than LP. The timing of study visit 1 tended to 
be earlier in LP, and gestation at delivery was earlier in OP. There were 
no differences in parity, birthweight percentile or standard deviation 
birthweight score. In nonpregnant participants, obese subjects were 
older and also had higher systolic and diastolic blood pressure than 
lean.
3.2 | Serum hormone profiles (08.00- 
11.00 hours and 16.00- 19.00 hours)
Figure 1 shows an example of serum glucocorticoid hormone profiles 
in nonpregnancy and during the 2 pregnancy visits, as illustrated by 
the data collected from the obese subject who was studied in non-
pregnancy (2 months prepregnancy), and during pregnancy at visit 
1 (17 + 2 weeks’ gestation) and visit 2 (30 + 6 weeks’ gestation). 
Levels of cortisol (Figure 1A), cortisone (Figure 1B), corticosterone 
(Figure 1C) and 11- dehydrocorticosterone (Figure 1D) were higher 
in pregnancy than in nonpregnancy, and all hormone levels increased 
with advancing gestation. Profiles of serum cortisol, cortisone, corti-
costerone and 11- dehydrocorticosterone for all other study partici-
pants are shown in Fig. S1. There were no samples from some subjects 
for the following reasons: did not attend visit 2 (LP2 n = 1 and OP2 
n = 2) and delivered before visit 2 (OP2 n = 1). With visual assessment 
of hormone profiles, we observed interindividual variation in pattern 
of profiles, but there were no obvious differences in characteristics 
between women that had particularly quiescent or dynamic profiles. 
Only one cortisol pulse was detected in the sampling from one subject 
so serum pulse characteristics are not reported. Interstitial fluid pulses 
were detected in the profiles of all subjects. Pulse characteristics are 
demonstrated in Table S3, and key findings are described below.
3.3 | Serum cortisol and cortisone
Fasting serum cortisol and cortisol AUC were significantly higher in 
pregnancy than nonpregnancy in lean and obese (Figure 2A,B). During 
pregnancy, cortisol AUC increased significantly with advancing gesta-
tion in lean, but not in obese (Figure 2A,B). Plasma ACTH rose with 
advancing gestation in both lean and obese groups (Figure 2C). The 
mean “highest peak” and “lowest trough” increased significantly with 
gestation in both lean and obese (Table S3).
Serum cortisone AUC was higher in pregnancy than nonpregnancy 
in both lean and obese. During pregnancy, overall cortisone levels rose 
(Figure 1B). Cortisone “lowest trough” increased significantly during 
pregnancy in obese, but not in lean (Table S3).
The mean cortisol:cortisone ratio of serum profiles was highest at 
pregnancy visit 1 (Table 2). The ratio of the baseline (08.00 hours) sam-
ple was significantly higher in pregnancy than nonpregnancy in obese 
but not in lean.
3.4 | Serum corticosterone and 
11- dehydrocorticosterone
Serum corticosterone levels were highest during pregnancy visit 
2 (Figure 1C) and “highest peak” increased significantly in obese 
during pregnancy (Table S3). Serum 11- dehydrocorticosterone 
levels were not significantly different with changing gestation 
(Figure 1D) and did not differ between obese and lean. The ratio of 
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corticosterone:11- dehydrocorticosterone of the baseline fasting sam-
ple was significantly higher at LP1 than LP2, but was not different in 
obese (Table 2).
3.5 | Interstitial fluid cortisol
Interstitial fluid data were available from LNP (n = 3), LP1 (n = 7), LP2 
(n = 6), ONP (n = 4), OP1 (n = 7) and OP2 (n = 3). There were no sam-
ples available from some subjects for the following reasons: techni-
cal issues (LP1 n = 1 and OP2 n = 1), participant declined (LP2 n = 1), 
did not attend for visit 2 (LP2 n = 1 and OP2 n = 2) and delivered be-
fore visit 2 (OP2 n = 1). Representative profiles from 2 subjects are 
shown in Figure 1E- F. Both pulsatility and the morning rise in cortisol 
were detected in the interstitial fluid sampling (Figure 1E- F). Pulses 
were detected in interstitial fluid samples. In lean women, pulse fre-
quency was consistently around 0.2 pulse/hours (approximately one 
pulse every 5 hours) and did not differ between lean nonpregnant 
and pregnant women at visit 1 and visit 2 (P = .591). In obese women, 
pulse frequency was similar to lean in nonpregnancy (0.22 ± 0.12 
pulse/hours). Pulse frequency was significantly lower with advancing 
gestation in obese women (visit 1: 0.18 ± 0.12 pulse/hours, visit 2: 
0.04 ± 0.003 pulse/hours; t test P = .025). There were no differences 
in pulse amplitude or mean concentration of the whole profiles with 
increasing gestation, or between lean and obese.
4  | DISCUSSION
Using 2 paradigms of altered HPA axis activity in pregnancy to in-
vestigate ultradian rhythms of glucocorticoid hormone secretion, we 
have demonstrated changes in serum glucocorticoid levels that occur 
across gestation and in pregnancies complicated by obesity. Total cir-
culating serum cortisol levels were higher in pregnancy than nonpreg-
nancy in lean and obese and increased significantly with advancing 
gestation in lean but not in obese. In addition, through measurement 
of interstitial fluid cortisol levels, we show evidence, for the first time, 
of tissue cortisol pulsatility in human pregnancy. In obese pregnancy, 
interstitial fluid pulse frequency was lower with advancing gestation.
The observation that serum cortisol AUC significantly increased 
during pregnancy in lean women, but not in obese women adds to the 
TABLE  1 Maternal and neonatal characteristics
Nonpregnant Pregnant
Lean (n = 3) Obese (n = 4) P- value Lean (n = 8) Obese (n = 7) P- value
Demographics Age (years) 36.3 (4.2) 39.0 (4.1) .435 35.1 (1.7) 29.3 (5.3) .026*
BMI (kg/m2) 22.3 (2.1) 36.5 (3.3) .001* 21.9 (1.6) 43.7 (5.3) <.0001*
Weight (kg) 66.8 (8.9) 101.2 (11.1) .006* 60.5 (7.1) 128.3 (16.6) <.0001*
Blood Pressure
Systolic (mmHg) 112 (8) 127 (9) .086 112 (8) 125 (9) .011*
Diastolic (mmHg) 70 (5.6) 79 (7.3) .048* 66 (6) 73 (8) .063
Parity N (%)
Primiparous N/A N/A N/A 4 (50) 3 (42.8) .736
Para 1 3 (37.5) 2 (28.1)
Para 2 1 (12.5) 2 (28.1)
Gestational age at 
study visit (days)
N/A N/A N/A
Pregnancy visit 1 132 (7.9) 147 (14.4) .03*
Pregnancy visit 2 228 (9.3) 235 (17.9) .39
Offspring 
Characteristics
Gestational at delivery 
(days)
N/A N/A N/A 285 (6.6) 266 (12.9) .003*
Offspring gender
Male N/A N/A 5 0 .01*
Female N/A 3 7
Infant size
Birthweight (g) N/A N/A N/A 3756 (82.8) 3283 (343.7) .01*
Birthweight centile 61.5 (14.0) 65.0 (25.4) .74
SDS Score 0.31 (0.4) 0.56 (0.9) .52
Age, BMI, weight and blood pressure were recorded at “booking” in pregnant subjects and study visit 1 in nonpregnant subjects. Parity was defined as 
“primiparous” (no previous pregnancies delivered after 24 weeks), “Para 1” (one previous delivery at 24 weeks) and “Para 2” (2 or more previous deliveries 
after 24 weeks gestation). Birthweight excludes one baby of an obese subject, who was born preterm at 34 weeks gestation. Data are mean (SD) or N (%). 
Key: BMI, body mass index; SDS, standard deviation birthweight score; N/A, not applicable. Significant figure is represented by asterisk (*).
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previous observations of lower morning fasting cortisol in obese26,27 
and supports the hypothesis that HPA axis activity is reduced through-
out the day in obese pregnancy.26 These data, together with our finding 
that interstitial fluid pulse frequency was lower with advancing gesta-
tion in obese pregnant women, contribute to our understanding of the 
changes in the HPA axis in obese pregnancy. Altered ultradian rhythm 
(characterized by reduced interstitial fluid pulse frequency) may be 
cause or consequence of decreased HPA axis in obese pregnancy. The 
drivers to the altered ultradian rhythm are poorly understood. With ro-
dent and sheep data demonstrating a mismatch in timing of CRH and 
cortisol pulses suggesting a subhypothalamic origin, it is hypothesized 
that interactions between central negative feedback at the pituitary 
and a delay in feedforward of ACTH on adrenal production of gluco-
corticoids drive ultradian rhythmicity.21 In the absence of repeated 
ACTH sampling, it is not possible to determine the influence of adrenal 
delay in cortisol release or altered central negative feedback on pulse 
frequency. Whether placental production of CRH contributes to the 
observed alteration in ultradian rhythm has not been studied.
To the best of our knowledge, we are the first to describe circu-
lating corticosterone levels across the day in human pregnancy and 
in nonpregnant women. Our finding of higher levels of corticoste-
rone in pregnancy than nonpregnancy suggests that like cortisol, the 
synthesis and release of this hormone are influenced by increased 
activation of the maternal HPA axis.3 Unlike cortisone, levels of 
11- dehydrocorticosterone did not change significantly with advancing 
gestation, suggesting that there may be a lesser breakdown of corticos-
terone than cortisol by 11β- HSD2 or alternative pathways of corticos-
terone clearance. For example, the ABC- transporters “p- glycoprotein” 
(P- gp, encoded by ABCB1) and “multidrug- resistant protein- 1″ (MRP1, 
encoded by ABCC1) which preferentially export cortisol or corticos-
terone, respectively, are present in the placenta,31 and ABCB1 mRNA 
expression is reported to be lower in placentas of pregnancies compli-
cated by severe obesity.32 Further studies are needed to understand 
the metabolism of corticosterone in pregnancy.
Our study is the first to measure interstitial fluid cortisol in women 
and in human pregnancy. We analysed the pulsatile characteristics 
FIGURE  1 A- F, Serum and interstitial fluid. Profiles of serum cortisol (A), cortisone (B), corticosterone (C) and 11- dehydrocorticosterone (D). Each 
figure demonstrates the individual hormone profiles of one representative subject who was studied 2 months prepregnancy, at visit 1 (17 + 2 weeks’ 
gestation) and visit 2 (third trimester (30 + 6 weeks’ gestation). Interstitial fluid cortisol profiles from 2 representative lean subjects obtained at 
17 + 2 and 31 weeks (E) and 18 + 3 and 32 + 3 weeks (F). Key: LOQ (limit of quantification) [Colour figure can be viewed at wileyonlinelibrary.com]
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of this data using the well- established Cluster algorithm.29 This is 
a statistically rigorous method that takes into account assay pre-
cision and is not adversely influenced by drifting baseline hormone 
secretion. Moreover, its model- independent nature means that it is 
not reliant on a priori assumptions about the system (eg parameters 
defined dynamics of hormone secretion or clearance) that we have 
F IGURE  2  (A- C) Fasting serum cortisol (A) increased with advancing gestation in lean and obese (one- way ANOVA: lean P = .017, obese 
P = .027) and was significantly higher at OP2 than OP1 (paired t test P = .012) and at OP2 than ONP (post hoc Tukey, P = .046). Cortisol AUC 
of serum profile (B) increased with advancing gestation in lean and obese (one- way ANOVA: lean P < .0001, obese P < .0001). AUC increased 
significantly between visit 1 and visit 2 in lean pregnant women (LP1 17937 ± 7141 nM vs LP2 2345 ± 7328 nM, P = .001), but not in obese 
(OP1 14498 ± 5794 vs OP2 24660 ± 8937 nM, P = .06). Plasma ACTH levels (C) increased during pregnancy and were significantly higher at 
pregnancy visit 2 than nonpregnancy in lean (P = .017) and obese (P = .045). Key: Lean nonpregnant (LNP), lean pregnant visit 1 (LP1), lean 
pregnant visit 2 (LP2), Obese nonpregnant (ONP), obese pregnant visit 1 (OP1), obese pregnant visit 2 (OP2). Data on graphs are mean (SEM). 
*P < .05, **P < .01, ***P < .0001
TABLE  2 Cortisol:Cortisone ratio
Lean Obese
LNP LP1 LP2 P1 P2 ONP OP1 OP2 P1 P2
Cortisol: Cortisone 
Baseline sample
4.6 (1.1) 7.9 (4.2) 6.9 (3.3) .22 .002* 4.3 (0.7) 6.7 (1.1) 5.7 (1.9) .007 .018*
Cortisol: Cortisone 
Mean overall
3.3 (0.4) 5.8 (3.1) 5.6 (2.1) .135 .004* 3.5 (0.4) 5.9 (0.9) 5.3 (1.8) .001 .078
Corticosterone: 
11- dehydrocorticosterone  
Baseline sample
2.5 (1.1) 6.4 (5.6) 5.9 (3.8) .439 .01* 8.0 (10.3) 4.2 (3.0) 4.8 (2.5) .728 .129
Cortisol: cortisone ratios of the first baseline fasting sample, mean of all samples, mean of first sampling time (08.00- 11.00 hours) and mean of second 
sampling time (16.00- 19.00 hours). One- way ANOVA found that cortisol:cortisone on the first baseline sample and throughout the profile was significantly 
higher in pregnancy than nonpregnancy in obese but not in lean. The paired t test showed that during pregnancy, fasting cortisol:cortisone was significantly 
higher at visit 1 than visit 2 in lean and in obese and that cortisol:cortisone ratio for the whole profile was significantly higher in lean but not in obese. 
Corticosterone: 11- dehydrocorticosterone was significantly higher at pregnancy visit 1 than visit 2 in lean, but not in obese. The ratio of corticosterone: 
11- dehydrocorticosterone was not assessed in whole profiles, as a higher proportion of samples were close to or below the limits of quantification. Data 
are mean (SD). One- way ANOVA P- value (P1). Paired t test of pregnancy visit 1 and visit 2 (P2). Key: LNP, lean nonpregnant; LP1 lean pregnant visit 1; LP2, 
lean pregnant visit 2; ONP, obese nonpregnant; OP1, obese pregnant visit 1; OP2, obese pregnant visit 2. Significant figure is represented by asterisk (*).
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little information about lean or obese pregnancy conditions. Using this 
algorithm, we demonstrated tissue cortisol pulsatility in women and in 
human pregnancy.
Studies of glucocorticoid pulsatility in pregnancy are limited, and 
to the best of our knowledge, there are no studies measuring both 
circulating and tissue interstitial fluid cortisol pulsatility in humans to 
which our data can be directly compared. Although the sample type, 
sampling frequency, gestation of pregnancy and lack of control group 
mean that our data cannot be directly compared, it is interesting to 
note that the interstitial fluid cortisol pulse frequency in our data was 
similar to the findings of a previous study of circulating serum cortisol 
in pregnancy. Magiakou et al25 used the detect pulse analysis method33 
to identify cortisol pulses in samples obtained at 30- minute intervals 
and observed 2- 3 pulses in a 12- hour period in pregnant women be-
tween 34 and 36 weeks’ gestation. Although the authors acknowl-
edged that the 30- minute sampling may have limited their detection of 
cortisol pulses, our observations of no serum cortisol pulses over the 
6- hour sampling frame in all but one subject, and the similar intersti-
tial fluid cortisol pulsatility to Magiakou et al, suggest that circulating 
cortisol pulsatility in pregnancy is decreased compared with the find-
ings of previous studies of circulating cortisol in men16,18 and in rats19 
reporting that pulses occur approximately hourly.16,18,19 We sampled 
serum more frequently (10- minute sampling interval) to increase the 
likelihood of identifying serum glucocorticoid pulses and conducted 
our studies with woman in the fasting state to exclude the pulsatile 
response that has been reported to occur in response to food.20 For 
these reasons, the sampling duration was shortened (6 hours at each 
visit) to limit the total blood volume sampled from pregnant women. 
We can only speculate that this shorter sampling time was not long 
enough to detect pulses using Cluster. This analytical method defines 
a pulse as a statistically significant increase in a “cluster” of hormone 
values followed by a statistically significant decrease in a second clus-
ter of values. The increase and decrease are judged in relation to the 
actual experimental error expressed by replicates in the presumptive 
nadir and peak results. We detected significant differences in the 
serum cortisol highest peaks and lowest troughs of serum profiles 
between study groups, and thus, with a longer sampling time and a 
greater number of samples, these may have been recognized as statis-
tically significant pulses.
We acknowledge that the frequency of cortisol pulses detected in 
interstitial fluid in lean women (approximately one pulse per 5 hours; 
not different between pregnant or nonpregnant women) is lower than 
has been reported in other studies of circulating cortisol pulse secre-
tion16 in men. Rodent studies have demonstrated that circadian and 
ultradian rhythms of glucocorticoids are highly synchronized between 
the blood and subcutaneous tissue34 so it would be reasonable to con-
sider that a similar frequency of cortisol pulses could be detected in 
interstitial fluid in our study. One possible reason for the lower pulse 
frequency detected in our interstitial fluid samples could be the fre-
quency of sampling (20- minute sampling, which allowed for continu-
ous sampling without changing tubing or microdialysis perfusion fluid 
during the study). However, in the absence of a longer period of serum 
sampling and identification of serum pulses, it is not possible to predict 
whether or not the reduction in pulse frequency we detected is physi-
ologically different from the approximately hourly secretion of cortisol 
pulses that has been reported in men.
Studies of the dynamic nature of glucocorticoids in humans are 
challenging, due to the need to obtain frequent samples. This is par-
ticularly pertinent in pregnant women where there may be ethical 
restrictions on the volume of blood sampled over the day. However, 
as our understanding of the role of the ultradian rhythm of cortisol 
in transcriptional regulation increases, and associations between an 
altered ultradian rhythm and disease processes are described,21 there 
is a need for dynamic studies. This is particularly so in the context of 
pregnancy, where the links between glucocorticoid exposure in utero 
and adverse foetal outcomes are well described, but mechanisms are 
not well understood. The implications of altered ultradian rhythm of 
cortisol in pregnancy are vast due to the wide- ranging effects of glu-
cocorticoids on foetal/placental gene expression or functions such as 
energy metabolism, lipolysis, lipid metabolism, gluconeogenesis and 
amino acid metabolism. This offers a potential underlying mechanism 
for the reduced foetal growth1 and increased risk of cardiovascular 
disease later in life2 that have been linked to increased glucocorticoid 
exposure. Conversely, for obese, it is plausible that the reduced mater-
nal ultradian rhythm and downstream consequences may contribute 
to the observed increased foetal growth and delay in gestation at de-
livery in pregnancies complicated by obesity.26
Strengths of our study include frequent sampling, matched serum 
and interstitial fluid sampling, sampling at 2 different points in ges-
tation and use of a robust statistical method for pulse detection and 
analysis. Obtaining serum samples via a peripheral cannula, and inter-
stitial fluid samples via a microdialysis catheter, meant that frequent 
sampling could take place without repeated insertion of needles, 
which would mount a stress response. Another strength is that serum 
samples were analysed with gold- standard analytical technique of liq-
uid chromatography- tandem mass spectrometry (LC- MS/MS),4 which 
also allowed the simultaneous detection of multiple analytes from a 
small volume of sample.
A limitation of our study is that the serum sampling periods were 
relatively short (two 3- hour study periods), during which only one 
cortisol pulse was detected in one subject’s sampling profile. These 
durations were selected so that sampling could be performed with 
subjects fasting, to avoid the known pulsatile response to food,20,35 
and so that a comparison could be made between morning and eve-
ning cortisol levels, whilst considering blood withdrawal restrictions of 
pregnant women. We recognize that our small sample size is a limita-
tion of this study. We acknowledge that mathematical algorithms for 
hormone pulse analysis have not been previously tested in a pregnant 
population, where there is an unknown contribution of the placenta to 
cortisol metabolism and clearance. We could not directly examine pla-
cental cortisol metabolism and transfer in this study. We used the ratio 
of cortisol:cortisone to infer total body 11β- HSD2 activity, which we 
assume in pregnancy is largely reflective of the placenta. The relative 
reduction in the ratio between visit 1 and visit 2 of pregnancy sug-
gests that the activity of 11β- HSD2 increases at the later gestations, 
thus serving to protect the foetus from exposure to excessively high 
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maternal cortisol levels during the third trimester.3 Further studies are 
needed to understand more about the contribution of the placenta to 
maternal and foetal glucocorticoid exposure.
To conclude, our study has demonstrated that total daytime circu-
lating maternal cortisol increases with advancing gestation in lean, but 
not obese women. Further, we have demonstrated the novel finding 
that tissue cortisol levels are pulsatile during human pregnancy and 
that pulse frequency is significantly lower with advancing gestation 
in obese pregnancy. This may be an underlying mechanism for the re-
duced HPA axis activity we previously reported in obese pregnancy.26 
A better understanding of the role of HPA axis dysregulation in ad-
verse pregnancy outcomes may inform us which high- risk pregnancies 
should be targeted to improve the health of the pregnant woman and 
the developing baby.
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